Pulmonary Mucormycosis in a Patient with Crohn Disease on Immunosuppressive Medications including Infliximab

Wright, Alissa; Steiner, Theodore S.; Bilawich, Ana Maria; English, John; Ryan, C. Frank

doi:10.1155/2013/363250

Cited by 8 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Marty et al [14] reported two cases of disseminated mucormycosis in allogeneic hematopoietic stem cell transplant recipients who received infliximab for the treatment of severe graft-versushost disease (GVHD). Visceral forms of TNF-associated mucormycosis have also been reported, primarily in patients with Crohn's disease receiving infliximab therapy: Devlin et al [15] described a case of gastrointestinal mucormycosis, and Wright et al [16] reported a lung abscess due to Rhizopus species. Finally, two cases of rhinocerebral mucormycosis in diabetic patients receiving infliximab for underlying autoimmune disease have been described [17,18].…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole

2015

View full text Add to dashboard Cite

Lipid formulations of amphotericin B remain the first-line antifungal therapy for invasive mucormycosis. Posaconazole is an alternative for salvage therapy, but its use as primary therapy is not recommended due to the paucity of clinical data. Here we describe the case of a 57-year-old diabetic woman receiving etanercept and prednisone for the treatment of psoriatic arthritis who developed primary cutaneous mucormycosis after a minor gardening injury. Infection was successfully treated with aggressive surgical debridement followed by a 6-week course of the new delayed-release tablet formulation of posaconazole and temporary withholding of anti-TNF treatment. Primary antifungal therapy with posaconazole can be considered in selected cases of cutaneous mucormycosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole

2015

View full text Add to dashboard Cite

show abstract

“…Mucormycosis: cutaneous [ 277 ], gastric perforation [ 233 ], disseminated [ 278 ], sinusitis [ 279 ], pulmonary [ 280 ]…”

Section: Immunosuppressive Therapy As a Risk Factor For Opportunistic Infectionmentioning

confidence: 99%

“…Toxoplasmosis: toxoplasmic retinochoroiditis [161,162], cerebral toxoplasmosis [163] Cryptococcosis: pneumonia and pulmonary infection [258,259], disseminated infection [260,261], meningitis [262,263], cutaneous infection [264] Pneumocystis jiroveci (carinii) pneumonia [265][266][267][268] Aspergillosis: allergic bronchopulmonary [269], pulmonary [270], sinus aspergillosis [271], central nervous system aspergillosis [272], disseminated [273] Candidiasis: systemic candidiasis [274], arthritis [275], oral candidiasis [276] Mucormycosis: cutaneous [277], gastric perforation [233], disseminated [278], sinusitis [279], pulmonary [280] Strongyloidiasis: hyperinfection [281] Tuberculosis (pulmonary) [282][283][284] CMV retinitis [285], disseminated CMV [286] IL-17A blockers (Ixekizumab) Toxoplasmosis: lymphadenopathy [164] reported species [43,[45][46][47][48]. Other reported Candida species were C. albicans, C. tropicalis, C. parapsilosis, C. orthopsilosis, and C. glabrata among COVID-19 patients [43,49].…”

Section: Il-1 Blockers Aspergillosis [257] Tnf-α Blockersmentioning

confidence: 99%

COVID-19-associated opportunistic infections: a snapshot on the current reports

2021

View full text Add to dashboard Cite

Treatment of the novel Coronavirus Disease 2019 (COVID-19) remains a complicated challenge, especially among patients with severe disease. In recent studies, immunosuppressive therapy has shown promising results for control of the cytokine storm syndrome (CSS) in severe cases of COVID-19. However, it is well documented that immunosuppressive agents ( e.g., corticosteroids and cytokine blockers) increase the risk of opportunistic infections. On the other hand, several opportunistic infections were reported in COVID-19 patients, including Aspergillus spp . , Candida spp . , Cryptococcus neoformans , Pneumocystis jiroveci ( carinii ), mucormycosis, Cytomegalovirus (CMV), Herpes simplex virus (HSV), Strongyloides stercoralis, Mycobacterium tuberculosis, and Toxoplasma gondii . This review is a snapshot about the main opportunistic infections that reported among COVID-19 patients. As such, we summarized information about the main immunosuppressive agents that were used in recent clinical trials for COVID-19 patients and the risk of opportunistic infections following these treatments. We also discussed about the main challenges regarding diagnosis and treatment of COVID-19-associated opportunistic infections (CAOIs). Supplementary Information The online version contains supplementary material available at 10.1007/s10238-021-00751-7.

show abstract

Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome

Feng

Sun

2018

Infection

View full text Add to dashboard Cite

show abstract

Pulmonary Mucormycosis in a Patient with Crohn Disease on Immunosuppressive Medications including Infliximab

Cited by 8 publications

References 10 publications

Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole

Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole

COVID-19-associated opportunistic infections: a snapshot on the current reports

Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome

Contact Info

Product

Resources

About